Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter

Mario Mandalà, G. Curigliano, P. Bucciarelli, G. Ferretti, P. M. Mannucci, M. Colleoni, A. Ventura, G. Peruzzotti, G. Severi, P. G. Pelicci, R. Biffi, F. Orsi, S. Cinieri, A. Goldhirsch

Research output: Contribution to journalArticle

Abstract

Background: To analyze the influence of the prothrombotic gene mutation factor V G1691A (factor V Leiden) and prothrombin G20210A on the risk of a first episode of catheter-related deep venous thrombosis (DVT) in a group of patients with breast cancer treated with chemotherapy. Patients and methods: Between January 1999 and February 2001, the occurrence of a first symptomatic DVT was investigated in a cohort of 300 consecutive patients with locally advanced or metastatic breast cancer treated at a single institution with fluorouracil-based chemotherapy, administered continuously through a totally implanted access port. A nested case-control study included 25 women (cases) with catheter-related DVT and 50 controls without DVT matched with cases for age, identical chemotherapy, stage of disease and prognostic features. The G1691A factor V and G20210A prothrombin mutation genotypes were analyzed. Results: Five cases [20%; 95% confidence interval (CI) 9% to 39%)] and two controls (4%; 95% CI 1% to 14%) were heterozygous carriers of G1691A factor V (P = 0.04). The age-adjusted odds ratio for catheter-related DVT was 6.1 (95 % CI 1.1-34.3). Only one patient (case) had the G20210A prothrombin gene mutation. Time from start of chemotherapy infusion to DVT was not significantly different between patients with (median 31 days) and without (median 43 days) G1691A factor V mutation (P = 0.6). Conclusions: Factor V Leiden carriers with locally advanced or metastatic breast cancer have an increased risk of developing catheter-related DVT during chemotherapy.

Original languageEnglish
Pages (from-to)590-593
Number of pages4
JournalAnnals of Oncology
Volume15
Issue number4
DOIs
Publication statusPublished - Apr 2004

Fingerprint

Subclavian Vein
Central Venous Catheters
Prothrombin
Venous Thrombosis
Thrombosis
Breast Neoplasms
Mutation
Drug Therapy
Catheters
Confidence Intervals
factor V Leiden
Fluorouracil
Genes
Case-Control Studies
Odds Ratio
Genotype

Keywords

  • Breast cancer
  • Factor V Leiden
  • Vein thrombosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{2d787e690b6c414a85f4ec71474f00c8,
title = "Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter",
abstract = "Background: To analyze the influence of the prothrombotic gene mutation factor V G1691A (factor V Leiden) and prothrombin G20210A on the risk of a first episode of catheter-related deep venous thrombosis (DVT) in a group of patients with breast cancer treated with chemotherapy. Patients and methods: Between January 1999 and February 2001, the occurrence of a first symptomatic DVT was investigated in a cohort of 300 consecutive patients with locally advanced or metastatic breast cancer treated at a single institution with fluorouracil-based chemotherapy, administered continuously through a totally implanted access port. A nested case-control study included 25 women (cases) with catheter-related DVT and 50 controls without DVT matched with cases for age, identical chemotherapy, stage of disease and prognostic features. The G1691A factor V and G20210A prothrombin mutation genotypes were analyzed. Results: Five cases [20{\%}; 95{\%} confidence interval (CI) 9{\%} to 39{\%})] and two controls (4{\%}; 95{\%} CI 1{\%} to 14{\%}) were heterozygous carriers of G1691A factor V (P = 0.04). The age-adjusted odds ratio for catheter-related DVT was 6.1 (95 {\%} CI 1.1-34.3). Only one patient (case) had the G20210A prothrombin gene mutation. Time from start of chemotherapy infusion to DVT was not significantly different between patients with (median 31 days) and without (median 43 days) G1691A factor V mutation (P = 0.6). Conclusions: Factor V Leiden carriers with locally advanced or metastatic breast cancer have an increased risk of developing catheter-related DVT during chemotherapy.",
keywords = "Breast cancer, Factor V Leiden, Vein thrombosis",
author = "Mario Mandal{\`a} and G. Curigliano and P. Bucciarelli and G. Ferretti and Mannucci, {P. M.} and M. Colleoni and A. Ventura and G. Peruzzotti and G. Severi and Pelicci, {P. G.} and R. Biffi and F. Orsi and S. Cinieri and A. Goldhirsch",
year = "2004",
month = "4",
doi = "10.1093/annonc/mdh146",
language = "English",
volume = "15",
pages = "590--593",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "4",

}

TY - JOUR

T1 - Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter

AU - Mandalà, Mario

AU - Curigliano, G.

AU - Bucciarelli, P.

AU - Ferretti, G.

AU - Mannucci, P. M.

AU - Colleoni, M.

AU - Ventura, A.

AU - Peruzzotti, G.

AU - Severi, G.

AU - Pelicci, P. G.

AU - Biffi, R.

AU - Orsi, F.

AU - Cinieri, S.

AU - Goldhirsch, A.

PY - 2004/4

Y1 - 2004/4

N2 - Background: To analyze the influence of the prothrombotic gene mutation factor V G1691A (factor V Leiden) and prothrombin G20210A on the risk of a first episode of catheter-related deep venous thrombosis (DVT) in a group of patients with breast cancer treated with chemotherapy. Patients and methods: Between January 1999 and February 2001, the occurrence of a first symptomatic DVT was investigated in a cohort of 300 consecutive patients with locally advanced or metastatic breast cancer treated at a single institution with fluorouracil-based chemotherapy, administered continuously through a totally implanted access port. A nested case-control study included 25 women (cases) with catheter-related DVT and 50 controls without DVT matched with cases for age, identical chemotherapy, stage of disease and prognostic features. The G1691A factor V and G20210A prothrombin mutation genotypes were analyzed. Results: Five cases [20%; 95% confidence interval (CI) 9% to 39%)] and two controls (4%; 95% CI 1% to 14%) were heterozygous carriers of G1691A factor V (P = 0.04). The age-adjusted odds ratio for catheter-related DVT was 6.1 (95 % CI 1.1-34.3). Only one patient (case) had the G20210A prothrombin gene mutation. Time from start of chemotherapy infusion to DVT was not significantly different between patients with (median 31 days) and without (median 43 days) G1691A factor V mutation (P = 0.6). Conclusions: Factor V Leiden carriers with locally advanced or metastatic breast cancer have an increased risk of developing catheter-related DVT during chemotherapy.

AB - Background: To analyze the influence of the prothrombotic gene mutation factor V G1691A (factor V Leiden) and prothrombin G20210A on the risk of a first episode of catheter-related deep venous thrombosis (DVT) in a group of patients with breast cancer treated with chemotherapy. Patients and methods: Between January 1999 and February 2001, the occurrence of a first symptomatic DVT was investigated in a cohort of 300 consecutive patients with locally advanced or metastatic breast cancer treated at a single institution with fluorouracil-based chemotherapy, administered continuously through a totally implanted access port. A nested case-control study included 25 women (cases) with catheter-related DVT and 50 controls without DVT matched with cases for age, identical chemotherapy, stage of disease and prognostic features. The G1691A factor V and G20210A prothrombin mutation genotypes were analyzed. Results: Five cases [20%; 95% confidence interval (CI) 9% to 39%)] and two controls (4%; 95% CI 1% to 14%) were heterozygous carriers of G1691A factor V (P = 0.04). The age-adjusted odds ratio for catheter-related DVT was 6.1 (95 % CI 1.1-34.3). Only one patient (case) had the G20210A prothrombin gene mutation. Time from start of chemotherapy infusion to DVT was not significantly different between patients with (median 31 days) and without (median 43 days) G1691A factor V mutation (P = 0.6). Conclusions: Factor V Leiden carriers with locally advanced or metastatic breast cancer have an increased risk of developing catheter-related DVT during chemotherapy.

KW - Breast cancer

KW - Factor V Leiden

KW - Vein thrombosis

UR - http://www.scopus.com/inward/record.url?scp=2342437469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342437469&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdh146

DO - 10.1093/annonc/mdh146

M3 - Article

C2 - 15033664

AN - SCOPUS:2342437469

VL - 15

SP - 590

EP - 593

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

ER -